Findings from FLAURA2, a phase III trial, show that adding chemotherapy to osimertinib, the preferred standard of care for patients with EGFR-mutant non–small cell lung cancer, significantly boosts progression-free survival. Serious side effects are also more likely with the combination, though, so patients should weigh the risk–benefit ratio.

You do not currently have access to this content.